Science and Research

Targeting neutrophil serine proteases in bronchiectasis

Persistent neutrophilic inflammation is a central feature in both the pathogenesis and progression of bronchiectasis (BE). Neutrophils release neutrophil serine proteases (NSPs), such as neutrophil elastase, cathepsin G and proteinase 3. When chronically high levels of free NSP activity exceed those of protective antiproteases, structural lung destruction, mucosal-related defects, further susceptibility to infection and worsening of clinical outcomes can occur. Despite the defined role of prolonged, high levels of NSPs in BE, no drug that controls neutrophilic inflammation is licensed for the treatment of BE. Previous methods of suppressing neutrophilic inflammation (such as direct inhibition of neutrophil elastase) have not been successful; however, an emerging therapy designed to address neutrophil-mediated pathology, inhibition of the cysteine protease cathepsin C (CatC, also known as dipeptidyl peptidase 1), is a promising approach to ameliorate neutrophilic inflammation, since this may reduce the activity of all NSPs implicated in BE pathogenesis, and not just neutrophil elastase. Current data suggest that CatC inhibition may effectively restore the protease-antiprotease balance in BE and improve disease outcomes as a result. Clinical trials for CatC inhibitors in BE have reported positive Phase III results. In this narrative review, we discuss the role of high NSP activity in BE, and how this feature drives the associated morbidity and mortality seen in BE. This review discusses therapeutic approaches aimed at treating neutrophilic inflammation in the BE lung, summarising clinical trial outcomes, and highlighting the need for more treatment strategies that effectively address chronic neutrophilic inflammation in BE.

  • Chalmers, J. D.
  • Mall, M. A.
  • Chotirmall, S. H.
  • O'Donnell, A. E.
  • Flume, P. A.
  • Hasegawa, N.
  • Ringshausen, F. C.
  • Watz, H.
  • Xu, J. F.
  • Shteinberg, M.
  • McShane, P. J.
Publication details
DOI: 10.1183/13993003.01050-2024
Journal: Eur Respir J
Work Type: Review
Location: Assoziierter Partner, ARCN, BREATH
Disease Area: CFBE
Partner / Member: BIH, Ghd, MHH
Access-Number: 39467608

DZL Engagements

chevron-down